CIRM grants ViaCyte $1.4M to create immune-evasive pluripotent stem cell lines
ViaCyte announced that the CIRM approved a grant of $1.4 million to support the initial development of immune-evasive pluripotent stem cell lines. The focus of the project will be to genetically engineer the Company’s CyT49 pluripotent stem cell line. December 15, 2017